# Research Grants Program Design

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Chief Scientific Officer
**Purpose**: Mark Egly Foundation's grant-making program for AATD research

---

## üìã Table of Contents

1. [Program Overview](#program-overview)
2. [Research Priorities](#research-priorities)
3. [Grant Types](#grant-types)
4. [Application Process](#application-process)
5. [Review & Selection](#review-selection)
6. [Award Management](#award-management)
7. [Impact Tracking](#impact-tracking)

---

## Program Overview

### Mission

**The Mark Egly Foundation Research Grants Program funds innovative AATD research to**:

- **Accelerate diagnosis** (reduce 7-8 year diagnostic delay)
- **Improve patient outcomes** (treatments, quality of life)
- **Advance scientific understanding** (genetics, pathophysiology, epidemiology)
- **Develop new tools** (diagnostics, therapeutics, devices)

**We prioritize research that directly impacts patients.**

---

### Program Philosophy

**Patient-Centered Research**:

- Research must have clear path to patient benefit (diagnosis, treatment, quality of life)
- Patient perspectives incorporated in research design
- Results communicated to patients in accessible language

**High-Risk, High-Reward**:

- Fund early-stage, innovative ideas (not yet ready for NIH)
- Support "moonshot" projects that could transform AATD care
- Accept that some projects will fail (that's science)

**Collaboration Over Competition**:

- Encourage multi-institutional partnerships
- Require data sharing (with appropriate patient protections)
- Foster AATD research community

**Speed to Impact**:

- Quick review cycles (60-90 days vs. 6-12 months for NIH)
- Minimal bureaucracy
- Interim results inform next funding decisions

---

### Budget Allocation

**Year 1** (2026):

- Total Research Budget: $100K (20% of overall budget)
- Pilot Grants: $75K (3 grants √ó $25K)
- Innovation Awards: $25K (1 award)

**Year 3** (2028):

- Total Research Budget: $500K (25% of overall budget)
- Pilot Grants: $250K (10 grants √ó $25K)
- Innovation Awards: $150K (3 awards √ó $50K)
- Clinical Research Grants: $100K (1 grant)

**Year 5** (2030):

- Total Research Budget: $1.5M (25% of overall budget)
- Pilot Grants: $500K (20 grants √ó $25K)
- Innovation Awards: $500K (5 awards √ó $100K)
- Clinical Research Grants: $500K (2-3 grants)

---

## Research Priorities

### Priority 1: Diagnostic Acceleration üî•

**Goal**: Cut diagnostic delay from 7-8 years to 3-4 years by 2030

**Research Topics**:

- **Point-of-care testing** (AAT glucometer, rapid diagnostic devices)
- **AI-driven diagnosis** (machine learning to flag AATD risk from EHR data)
- **Biomarker discovery** (new markers beyond AAT level)
- **Screening strategies** (optimal populations, cost-effectiveness)
- **Provider education impact** (does CME reduce diagnostic delay?)

**Why This Matters**:

- Diagnostic delay is #1 problem for AATD patients
- Mark's personal mission (7-8 years to diagnose himself)
- Foundation's north star metric (Diagnostic Delay Time)

**Funding Allocation**: 40-50% of research budget

---

### Priority 2: Treatment Innovation

**Goal**: Expand treatment options beyond augmentation therapy

**Research Topics**:

- **Novel therapeutics** (gene therapy, CRISPR, small molecules)
- **Augmentation therapy optimization** (dosing, delivery, personalized medicine)
- **Lung-protective strategies** (prevent emphysema progression)
- **Liver disease treatments** (AATD liver disease underserved)
- **Drug repurposing** (existing drugs for AATD)

**Why This Matters**:

- Current treatment (augmentation therapy) expensive, burdensome (weekly infusions)
- No cure exists
- Many patients not eligible for augmentation therapy

**Funding Allocation**: 25-30% of research budget

---

### Priority 3: Quality of Life & Patient Outcomes

**Goal**: Improve day-to-day life for AATD patients

**Research Topics**:

- **Psychosocial impact** (anxiety, depression, quality of life)
- **Exercise interventions** (pulmonary rehab, optimal exercise for AATD)
- **Patient navigation** (does navigation improve outcomes?)
- **Symptom management** (breathlessness, fatigue, exacerbations)
- **Caregiver burden** (support for families)

**Why This Matters**:

- AATD affects every aspect of life (physical, emotional, social, financial)
- Research often focuses on biology, not lived experience
- Patients want better quality of life, not just longer life

**Funding Allocation**: 15-20% of research budget

---

### Priority 4: Epidemiology & Health Disparities

**Goal**: Understand who gets diagnosed, who doesn't, and why

**Research Topics**:

- **Diagnostic delay disparities** (race, ethnicity, geography, insurance status)
- **Underdiagnosed populations** (why are certain groups missed?)
- **Natural history studies** (long-term outcomes for diagnosed vs. undiagnosed)
- **Healthcare utilization** (ER visits, hospitalizations, costs)
- **Screening uptake** (barriers to testing)

**Why This Matters**:

- Only 10% of AATD patients diagnosed (90% undiagnosed)
- Health disparities likely (not all patients have equal access)
- Understanding "who, when, why" improves detection strategies

**Funding Allocation**: 10-15% of research budget

---

## Grant Types

### 1. Pilot Grants ($25K, 1 year)

**Purpose**: Seed funding for early-stage, preliminary research

**Ideal Projects**:

- Proof-of-concept studies
- Feasibility studies
- Preliminary data to support larger grant applications (NIH, etc.)
- Novel ideas not yet funded

**Examples**:

- "Can wearable fitness trackers predict AATD exacerbations?" ($25K, 12 months)
- "Pilot study: AI algorithm to flag AATD risk from chest X-rays" ($25K, 12 months)
- "Patient perspectives on AAT glucometer: qualitative study" ($20K, 10 months)

**Eligibility**:

- Junior faculty (assistant professors, within 5 years of PhD/MD)
- Established faculty exploring new research area
- Interdisciplinary teams (encouraged)

**Award Details**:

- $25K total costs (direct + indirect)
- 1 year (with no-cost extension option for 6 months)
- 10-15 grants awarded/year (by Year 3)

---

### 2. Innovation Awards ($50-100K, 1-2 years)

**Purpose**: Fund high-risk, high-reward transformative research

**Ideal Projects**:

- Disruptive technologies (AAT glucometer, gene therapy)
- "Moonshot" ideas (ambitious but feasible)
- Multi-institutional collaborations
- Technology development (devices, apps, platforms)

**Examples**:

- "Development of point-of-care AAT testing device" ($100K, 18 months)
- "CRISPR gene editing to correct AATD mutation (in vitro)" ($75K, 2 years)
- "Mass production of recombinant AAT protein for research use" ($50K, 1 year)

**Eligibility**:

- Any career stage
- Partnerships encouraged (academia + industry, multi-institution)
- Track record of innovation

**Award Details**:

- $50-100K total costs
- 1-2 years
- 3-5 grants awarded/year (by Year 3)

---

### 3. Clinical Research Grants ($100-250K, 2-3 years)

**Purpose**: Fund patient-facing clinical research (trials, observational studies)

**Ideal Projects**:

- Clinical trials (Phase I/II for new treatments)
- Intervention studies (does X improve outcome Y?)
- Observational studies (natural history, biomarkers)
- Patient registry studies

**Examples**:

- "Randomized trial: Patient navigation vs. usual care for AATD patients" ($150K, 2 years)
- "Prospective study: Diagnostic delay in diverse populations" ($200K, 3 years)
- "Phase I trial: Novel AAT protein variant for augmentation therapy" ($250K, 3 years)

**Eligibility**:

- Clinical researchers (MDs, MD-PhDs)
- IRB approval required (or pending at application)
- Must have clinical research infrastructure (study coordinator, etc.)

**Award Details**:

- $100-250K total costs
- 2-3 years
- 1-3 grants awarded/year (starting Year 3)

---

### 4. Data Science & AI Grants ($25-50K, 1 year)

**Purpose**: Leverage data science, machine learning, AI to solve AATD problems

**Ideal Projects**:

- AI/ML algorithms (diagnostic risk prediction, image analysis)
- Big data analyses (EHR data, claims data, genomics)
- Natural language processing (extract AATD data from medical records)
- Mobile health (apps, wearables)

**Examples**:

- "Machine learning to predict AATD from routine lab values" ($30K, 12 months)
- "NLP algorithm to identify undiagnosed AATD patients in EHR" ($50K, 18 months)
- "App to track symptoms + predict exacerbations" ($40K, 12 months)

**Eligibility**:

- Data scientists, biostatisticians, computer scientists
- Partnerships with clinicians (required‚Äîno pure CS projects)
- Access to data (real or synthetic)

**Award Details**:

- $25-50K total costs
- 1 year
- 2-5 grants awarded/year (starting Year 2)

---

### 5. Patient-Led Research Grants ($10-25K, 1 year)

**Purpose**: Fund research led by AATD patients or patient organizations

**Ideal Projects**:

- Community-based participatory research
- Patient-reported outcomes research
- Advocacy research (policy analysis, health equity)
- Patient-generated data (surveys, registries)

**Examples**:

- "Patient survey: Impact of diagnostic delay on mental health" ($15K, 9 months)
- "Community-led AATD screening events (research component)" ($20K, 12 months)
- "Patient perspectives on gene therapy" ($10K, 6 months)

**Eligibility**:

- AATD patients (with research mentor)
- Patient advocacy organizations
- Community-based organizations

**Award Details**:

- $10-25K total costs
- 1 year
- 2-3 grants awarded/year (starting Year 2)

---

## Application Process

### Step 1: Letter of Intent (LOI)

**Purpose**: Screen projects for fit before full application

**Required Information**:

- Project title
- Lead researcher (name, institution, brief bio)
- Brief description (250 words max)
- Research priority area (which of the 5 priorities?)
- Requested amount
- Contact information

**Submission**:

- Online form (Foundation website)
- Rolling submissions (reviewed monthly)
- Decision within 2 weeks (invite to full application or not)

**Outcome**:

- ‚úÖ Invited to submit full application (~50% of LOIs)
- ‚ùå Not invited (feedback provided)

---

### Step 2: Full Application

**Required Documents**:

1. **Application Form**:
   - Project title
   - Research team (lead PI, co-investigators, collaborators)
   - Institution(s)
   - Grant type requested
   - Amount requested
   - Duration

2. **Research Plan** (5 pages max):
   - Specific Aims
   - Background & Significance
   - Preliminary Data (if applicable)
   - Research Design & Methods
   - Expected Outcomes
   - Patient Impact (how will this help AATD patients?)
   - Timeline (milestones)

3. **Budget & Justification** (2 pages max):
   - Detailed budget (personnel, supplies, travel, other)
   - Budget justification (why each item is necessary)
   - Facilities & Resources (what institution provides)
   - Other funding (current grants, pending applications)

4. **Biosketch/CV** (NIH biosketch format, 5 pages max per person):
   - Lead PI
   - Co-investigators (if any)

5. **Letters of Support** (optional, 1 page each):
   - Collaborators
   - Institution (for junior faculty)
   - Community partners

6. **IRB Approval** (or pending, for clinical research)

7. **Patient Partner Letter** (encouraged):
   - Letter from AATD patient partner describing involvement in project

**Submission**:

- Online portal (Foundation website)
- Rolling deadlines (quarterly: March 1, June 1, Sept 1, Dec 1)
- Review cycle: 60-90 days

---

### Step 3: Review Process

**Peer Review Panel**:

- 5-7 reviewers:
  - AATD clinical experts (pulmonologists, hepatologists)
  - Basic scientists (genetics, cell biology)
  - Patient representatives (2 AATD patients)
  - Methodologists (biostatisticians, epidemiologists)
  - Community stakeholders (rare disease advocates)

**Review Criteria** (scored 1-5, 5 = excellent):

1. **Significance** (25%):
   - Addresses important AATD problem?
   - Will advance field?
   - Clear patient benefit?

2. **Innovation** (20%):
   - Novel approach?
   - Challenges existing paradigms?
   - High-risk, high-reward?

3. **Approach** (25%):
   - Rigorous methods?
   - Appropriate design?
   - Feasible in timeframe/budget?

4. **Investigator** (15%):
   - Qualified to conduct research?
   - Track record of productivity?
   - Strong team?

5. **Environment** (10%):
   - Institutional support?
   - Necessary resources available?

6. **Patient Impact** (5%):
   - How will this help AATD patients?
   - Patient involvement in project?

**Overall Impact Score**: Average of 6 criteria

**Funding Priority**:

- Impact Score ‚â• 4.5: Fund (if budget allows)
- Impact Score 3.5-4.4: Discuss (may fund if exceptional)
- Impact Score < 3.5: Do not fund

---

### Step 4: Funding Decision

**Scientific Advisory Board Review**:

- Board reviews peer review scores + summaries
- Considers portfolio balance (early vs. late stage, topics, institutions)
- Makes final funding recommendations

**Board of Directors Approval**:

- Board approves funding slate
- Typically follows Scientific Advisory Board recommendations

**Notification**:

- Applicants notified within 90 days of submission
- Funded applicants: Award letter + grant agreement
- Unfunded applicants: Reviewer feedback provided

---

## Review & Selection

### Peer Review Panel Composition

**AATD Clinical Experts** (2):

- Pulmonologist with AATD expertise
- Hepatologist (AATD liver disease)

**Basic Scientists** (2):

- Geneticist
- Cell/molecular biologist

**Methodologists** (1):

- Biostatistician or epidemiologist

**Patient Representatives** (2):

- AATD patients (diverse backgrounds)
- Trained in grant review process

**Optional**:

- Data scientist (for AI/ML grants)
- Community stakeholder (for patient-led research)

**Panel Chair**: Chief Scientific Officer or Senior Researcher

---

### Review Meeting

**Format**: Virtual meeting (Zoom), 2-3 hours

**Agenda**:

1. Welcome + conflict of interest disclosure
2. Review each application:
   - Assigned reviewers present (2 per application)
   - Open discussion (all panelists)
   - Scoring (private, then revealed)
   - Consensus score
3. Rank applications by score
4. Funding recommendations

**Scoring**:

- Each reviewer scores independently (1-5 scale)
- Scores averaged ‚Üí Overall Impact Score
- Top-scoring applications recommended for funding

---

### Conflict of Interest Policy

**Reviewers must disclose**:

- Financial relationships (consulting, stock, grants)
- Personal relationships (collaborators, mentors, mentees)
- Institutional conflicts (same institution as applicant)

**Recusal Required If**:

- Direct financial interest in outcome
- Close collaborator (co-authored paper in last 3 years)
- Current or former trainee/mentor
- Family member

**Recused Reviewers**:

- Leave room during discussion of application
- Do not score application
- Do not participate in funding decision

---

## Award Management

### Award Notification

**Funded Applicants Receive**:

- Award letter (congratulations!)
- Grant agreement (terms and conditions)
- Budget (approved amount, itemized)
- Reporting requirements (progress reports, final report)
- Payment schedule (upfront 50%, then quarterly or biannually)

**Unfunded Applicants Receive**:

- Summary of reviewer feedback (anonymous)
- Overall Impact Score
- Encouragement to revise and resubmit

---

### Grant Agreement Terms

**Standard Terms**:

- Award period (start date, end date)
- Approved budget (direct costs, indirect costs <10%)
- Reporting requirements (see below)
- Intellectual property (inventor owns, Foundation has royalty-free license for nonprofit use)
- Data sharing (de-identified data shared in AATD Research Database)
- Acknowledgment (grantees must acknowledge Foundation in publications)

**Special Conditions** (if applicable):

- IRB approval required before funds released
- Animal protocol approval (if applicable)
- Budget restrictions (no equipment >$5K without prior approval)

---

### Reporting Requirements

**Progress Reports**:

- **Frequency**: Biannual (every 6 months)
- **Due**: 30 days after reporting period ends
- **Content**:
  - Scientific progress (vs. specific aims)
  - Challenges encountered
  - Budget update (spent vs. remaining)
  - Publications, presentations, media
  - Next steps

**Final Report**:

- **Due**: 60 days after project end
- **Content**:
  - Summary of findings (lay language for patients)
  - Scientific summary (for researchers)
  - Impact on AATD field
  - Publications (published or in preparation)
  - Follow-on funding secured (NIH grants, etc.)
  - Lessons learned

**Financial Reports**:

- **Due**: Annually + final report
- **Content**:
  - Expenditures by category (personnel, supplies, travel, other)
  - Unspent funds (return or request extension)

---

### Grant Extensions

**No-Cost Extensions**:

- Allowed: Up to 6 months (with justification)
- Process: Email request 60 days before project end
- Approval: Chief Scientific Officer (no board approval needed)

**Budget Modifications**:

- <10% reallocation: No approval needed
- > 10% reallocation: Email request, CSO approval
- > 25% reallocation: Board approval required

---

### Grant Termination

**Termination for Cause**:

- Non-compliance with grant agreement
- Misuse of funds
- Failure to submit required reports
- Research misconduct

**Procedure**:

- Written notice (30 days to cure)
- If not cured: Immediate termination
- Unspent funds returned

**Termination by Grantee**:

- Allowed (with 60 days notice)
- Unspent funds returned
- Final report required (even if project incomplete)

---

## Impact Tracking

### Short-Term Outcomes (1-2 years)

**Metrics**:

- **Publications**: Peer-reviewed papers, abstracts, posters
- **Presentations**: Conferences, seminars, webinars
- **Follow-On Funding**: NIH grants, industry funding, other foundations
- **Collaborations**: New partnerships formed
- **Training**: Students/postdocs trained
- **Media**: News coverage, blog posts, social media

**Data Collection**:

- Annual surveys to grantees
- PubMed alerts (for publications)
- NIH RePORTER (for follow-on grants)

---

### Medium-Term Outcomes (3-5 years)

**Metrics**:

- **Clinical Impact**: Clinical trials launched, FDA approvals, clinical guidelines updated
- **Policy Impact**: Policy changes, advocacy wins
- **Patient Impact**: New diagnostics, treatments, or services available
- **Community Impact**: AATD research community growth (conferences, journals, networks)

**Data Collection**:

- Grantee surveys (every 2 years post-grant)
- Literature reviews (citation analysis)
- Stakeholder interviews (clinicians, patients, advocates)

---

### Long-Term Outcomes (5-10 years)

**Metrics**:

- **Diagnostic Delay Reduction**: North star metric (7-8 years ‚Üí 3-4 years by 2030)
- **Lives Saved**: Estimated lives saved by earlier diagnosis
- **Quality of Life**: Patient-reported outcomes (QOL scores)
- **Health Equity**: Reduction in diagnostic delay disparities

**Data Collection**:

- AATD Research Database (longitudinal data)
- National surveys (AATD patients)
- Health system data (diagnostic patterns)

---

### Success Stories

**Pilot Grant ‚Üí NIH R01** (Example):

- 2026: MEF Pilot Grant ($25K) ‚Üí Preliminary data on AI diagnostic algorithm
- 2027: NIH R01 submitted ($2M, 5 years)
- 2028: NIH R01 funded ‚Üí Full-scale AI diagnostic tool development
- 2030: AI tool deployed in 50 health systems ‚Üí Diagnostic delay cut 30%
- **Impact**: $25K seed funding ‚Üí $2M NIH grant ‚Üí Thousands diagnosed earlier

**Innovation Award ‚Üí Startup** (Example):

- 2027: MEF Innovation Award ($100K) ‚Üí AAT glucometer prototype
- 2028: Patent filed, seed funding ($1M) ‚Üí AAT Diagnostics, Inc. founded
- 2030: FDA clearance ‚Üí AAT glucometer on market
- **Impact**: $100K seed funding ‚Üí Commercial product ‚Üí Home testing for AATD

**Patient-Led Research ‚Üí Policy Change** (Example):

- 2026: MEF Patient-Led Grant ($15K) ‚Üí Survey of diagnostic delay disparities
- 2027: Results published ‚Üí Media coverage ‚Üí Advocacy campaign
- 2028: State legislation passed ‚Üí Mandatory AATD testing for COPD patients
- **Impact**: $15K grant ‚Üí Policy change ‚Üí Thousands diagnosed earlier

---

## Summary

**Mark Egly Foundation Research Grants Program**:

- ‚úÖ **Patient-Centered**: Research must help AATD patients
- ‚úÖ **High-Impact**: Priority on diagnostic acceleration (north star)
- ‚úÖ **Innovative**: High-risk, high-reward projects
- ‚úÖ **Fast**: 60-90 day review (vs. 6-12 months for NIH)
- ‚úÖ **Rigorous**: Peer review by experts + patients
- ‚úÖ **Collaborative**: Data sharing, partnerships encouraged
- ‚úÖ **Transparent**: Public reporting of funded projects

**Year 1 Goals**:

- Launch program
- Award 3-5 pilot grants ($75K total)
- Build review infrastructure
- Track outcomes

**Year 5 Goals**:

- Award 25-30 grants/year ($1.5M total)
- Portfolio balance (pilot, innovation, clinical, data science, patient-led)
- Evidence of impact (publications, follow-on funding, clinical tools)
- Diagnostic delay reduction (progress toward 3-4 year goal)

---

**Questions?**

**Mark Egly Foundation**
üìß Email: research@markeglyfoundation.org
üåê Website: MarkEglyFoundation.org/Research

---

**Approved by**: Scientific Advisory Board & Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Funding the research that will end diagnostic delays."_

**‚Äî Mark Egly Foundation**
